Literature DB >> 8762386

Prioritising elective care: a cost utility analysis of orthopaedics in the north west of England.

M James1, S St Leger, K V Rowsell.   

Abstract

STUDY
OBJECTIVE: To produce a priority list for purchasers to use when purchasing elective care in the speciality of orthopaedics so that efficiency in health care purchasing (that is, maximising the benefit per unit of resource available for the resident population) can be achieved.
DESIGN: The study used cost utility analysis in the elective speciality of orthopaedics. The diagnostic groups in the study were chosen on the basis of those conditions that constituted the greatest proportion of the orthopaedic waiting list, and consequently the greatest proportion of activity within the speciality. Costs were derived by two methods: the extra contractual referral tariff (ECR) and individual patient based costings. Outcome was assessed before surgery and again approximately six months afterwards. The outcome of the procedures was derived in two ways: Rosser and EuroQol indices.
SETTING: The study took place at Wrightington hospital, a specialist orthopaedic hospital in north west England. PATIENTS: Prospective assessments were obtained from 99 patients for nine orthopaedics procedures. All the patients were individually interviewed on each occasion. Rosser and EuroQol assessments were completed for each patient by the patient and the patient's consultant before and after surgery. MAIN
RESULTS: Priority lists presenting cost utility rankings for each of the procedures were derived from the patients' and consultants' assessments.
CONCLUSIONS: It is feasible to generate priority lists in a systematic way. Purchasers may then use the results from these priority lists to help them maximise the benefits per unit of resource for their resident population.

Entities:  

Mesh:

Year:  1996        PMID: 8762386      PMCID: PMC1060250          DOI: 10.1136/jech.50.2.182

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  9 in total

1.  EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway.

Authors:  E Nord
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

2.  Priority setting: lessons from Oregon.

Authors:  J Dixon; H G Welch
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

3.  Valuation of health states by the general public: feasibility of a standardized measurement procedure.

Authors:  M L Essink-Bot; G J Bonsel; P J van der Maas
Journal:  Soc Sci Med       Date:  1990       Impact factor: 4.634

4.  Economic appraisal of new technology in the absence of survival data--the case of total hip replacement.

Authors:  H G Daellenbach; W J Gillespie; P Crosbie; U S Daellenbach
Journal:  Soc Sci Med       Date:  1990       Impact factor: 4.634

5.  Long-term results of cemented total hip arthroplasty.

Authors:  N S Eftekhar
Journal:  Clin Orthop Relat Res       Date:  1987-12       Impact factor: 4.176

6.  The long-term results of the Liverpool Mark II knee prosthesis.

Authors:  S J Walker; P Sharma; N Parr; M E Cavendish
Journal:  J Bone Joint Surg Br       Date:  1986-01

7.  Prioritising waiting lists.

Authors:  C Gudex; A Williams; M Jourdan; R Mason; J Maynard; R O'Flynn; M Rendall
Journal:  Health Trends       Date:  1990

8.  EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise.

Authors:  R G Brooks; S Jendteg; B Lindgren; U Persson; S Björk
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

9.  A comparison of total hip replacement in patients aged 69 years or less and 70 years or over.

Authors:  G K Wilcock
Journal:  Gerontology       Date:  1981       Impact factor: 5.140

  9 in total
  9 in total

1.  The Cost-Effectiveness of Surgical Fixation of Distal Radial Fractures: A Computer Model-Based Evaluation of Three Operative Modalities.

Authors:  Prashant V Rajan; Rameez A Qudsi; George S M Dyer; Elena Losina
Journal:  J Bone Joint Surg Am       Date:  2018-02-07       Impact factor: 5.284

2.  Assessing the value of a total joint replacement.

Authors:  David B Bumpass; Ryan M Nunley
Journal:  Curr Rev Musculoskelet Med       Date:  2012-12

Review 3.  Total hip arthroplasty: areview of advances, advantages and limitations.

Authors:  Xin-Wei Liu; Ying Zi; Liang-Bi Xiang; Yu Wang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Use of the EuroQoL among elderly acute care patients.

Authors:  J Coast; T J Peters; S H Richards; D J Gunnell
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

5.  Does age or bilateral disease influence the value of hip arthroplasty?

Authors:  Bryan M Lawless; Meridith Greene; James Slover; Young-Min Kwon; Henrik Malchau
Journal:  Clin Orthop Relat Res       Date:  2012-04       Impact factor: 4.176

Review 6.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial.

Authors:  A W Wu; K L Jacobson; K D Frick; R Clark; D A Revicki; K A Freedberg; J Scott-Lennox; J Feinberg
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

8.  The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study.

Authors:  Matthias Vogl; Rainer Wilkesmann; Christian Lausmann; Werner Plötz
Journal:  BMC Health Serv Res       Date:  2014-08-15       Impact factor: 2.655

9.  Robotic- and orthosensor-assisted versus manual (ROAM) total knee replacement: a study protocol for a randomised controlled trial.

Authors:  Nick D Clement; Michelle Bardgett; Steven Galloway; Y Jenny Baron; Karen Smith; David J Weir; David J Deehan
Journal:  Trials       Date:  2022-01-22       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.